)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Sangamo Therapeutics (SGMO) investor relations material
Sangamo Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Positive topline results from the registrational STAAR study in Fabry disease, with FDA agreement on eGFR slope as the primary approval basis and BLA submission expected as early as Q1 2026.
Initiated first clinical site for the Phase 1/2 STAND study in chronic neuropathic pain, with first patient dosing expected fall 2025 and preliminary efficacy data anticipated in 2026.
Advanced preclinical prion disease program, with CTA submission anticipated mid-2026 and clinical data expected mid-2027.
Raised $21 million in net proceeds from an equity offering, with $38.3 million in cash and equivalents as of June 30, 2025, expected to fund operations into Q4 2025.
Ongoing business development and partnership discussions for Fabry and hemophilia A programs; no commercialization partner secured for Fabry as of report date.
Financial highlights
Q2 2025 revenue was $18.3 million, up from $0.36 million in Q2 2024, mainly due to an $18 million upfront payment from Lilly.
Cash and cash equivalents totaled $38.3 million as of June 30, 2025.
Q2 2025 net loss was $20.0 million ($0.08/share), improved from $36.1 million ($0.18/share) in Q2 2024.
GAAP operating expenses for Q2 2025 were $36.2 million; non-GAAP operating expenses were $33.0 million.
Raised $21.1 million in May 2025 underwritten offering and $17.6 million through at-the-market sales in H1 2025.
Outlook and guidance
Cash runway expected to fund operations into Q4 2025; additional capital is required to fund operations and R&D beyond that point.
Anticipates BLA submission for Fabry disease gene therapy as early as Q1 2026, contingent on funding and partnership.
First patient dosing for ST-503 in iSFN expected fall 2025; preliminary efficacy data anticipated Q4 2026.
CTA submission for prion disease program expected mid-2026.
Ongoing efforts to secure commercialization partners for Fabry and hemophilia A programs; failure to do so may require further cost reductions or cessation of operations.
What specific partner concerns remain for Fabry?
How does Nav1.7 strategy compare to Nav1.8?
Why did one Fabry patient resume ERT?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sangamo Therapeutics earnings date
Q3 202511 Nov, 2025
Next Sangamo Therapeutics earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in therapeutic genome editing. The company's lead program is focused on treating inherited blood disorder beta-thalassemia and sickle cell disease by ex vivo genome editing in hematopoietic stem and progenitor cells from adult patients. It is also focusing on genome editing for HIV/AIDS; hemophilia; Huntington's disease; LCA6; other rare and infectious diseases; cancer and degenerative conditions. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage